Skip to Content

Regenicin Inc RGIN

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RGIN is trading at a 691% premium.
Price
$0.00
Fair Value
$4.76
Uncertainty
Extreme
1-Star Price
$2.71
5-Star Price
$4.64
Economic Moat
Fktsgbs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RGIN is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.01
Bid/Ask
$0.01 / $0.01
Market Cap
$15,348.31
Volume/Avg
15,000 / 204,651

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
3

Valuation

Metric
RGIN
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
RGIN

Financial Strength

Metric
RGIN
Quick Ratio
0.66
Current Ratio
0.66
Interest Coverage
−24.26
Quick Ratio
RGIN

Profitability

Metric
RGIN
Return on Assets (Normalized)
−19.66%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
RGIN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
KrmtlrpsVgzd$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
QzjzsrxnPddjc$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
GskkhylrTfjgby$121.2 Bil
Moderna Inc
MRNA
FwpndnmtWsp$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
YpzmzswBfpxkc$33.0 Bil
argenx SE ADR
ARGX
PznrqnhkRtmmc$27.9 Bil
BioNTech SE ADR
BNTX
VpfkjjbdFyhxf$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
WrcdcmfhqNshplrz$16.1 Bil
United Therapeutics Corp
UTHR
LlwvppbbcVjr$14.3 Bil
Incyte Corp
INCY
XtkrpyyslSqgmj$12.5 Bil

Sponsor Center